4 years ago

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems

Michelle Geddes, Maria Antonietta Aloe Spiriti, Susanna Fenu, Brian Leber, Janika Francis, Flavia Salvi, Marino Clavio, Paolo Danise, Pellegrino Musto, Alessandro Andriani, Thomas J. Nevill, Elena Crisà, Esther Natalie Oliva, Rena Buckstein, Anna Lina Piccioni, Nancy Zhu, Richard Wells, Luana Fianchi, Carlo Finelli, Chiara Salvetti, Karen W. Yee, Antonella Poloni, John M. Storring, Roberto Latagliata, Luca Maurillo, Mitchell Sabloff, Enrico Balleari, Brett Houston, Daniela Cilloni, Bernardino Allione, Alessandro Sanna, Svitlana Gumenyuk, Valeria Santini, Heather Leitch, Francesco Buccisano
Background In ‘real-life’, the Nordic score guides Erythropoietic stimulating agent (ESA) use in lower-risk myelodysplastic syndrome (MDS) with predicted response rates of 25% or 74%. As new treatments emerge, a more discriminating score is needed. Objectives To validate existing ESA predictive scores and develop a new score that identifies non-responders. Methods ESA-treated patients were identified in 3 MDS registries in Italy and Canada (FISM 555, GROM 233, and MDS-CAN 208). Clinical and disease-related variables were captured. Nordic, MDS-CAN, and IPSS-R-based ESA scores were calculated and documented ESA responses compared. Results 996 ESA-treated patients were identified. Overall response rate (ORR) was 59%. The database was randomly divided into balanced derivation (n = 463) and validation (n = 462) cohorts. By multivariate analysis, transfusion independence, erythropoietin (EPO) level <100 IU/L, and IPSS low-risk were independently predictive of response. Assigning a score of 1 to each resulted in a scoring system of 0-3 with response rates of 23%, 43%, 67%, and 85%. ORR was concordant in the validation cohort. The ‘ITACA’ score had the highest discriminating power of response. Conclusion ITACA is an internally-validated predictive SS of ESA response in real-life ‘good risk’ MDS patients derived from a large international dataset that surpasses others. The incorporation of biologic markers to better identify non-responders is still needed.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/ajh.24842

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.